A Phase II trial of IMU-838 in patients with Crohn's disease (CALDOSE-2).
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CALDOSE-2
- Sponsors Immunic
- 07 Jan 2019 According to a Vital Therapies media release, the company intends to initiate the trial throughout the course of 2019.
- 15 Jan 2018 New trial record
- 11 Jan 2018 According to an Immunic media release, the company is planning to commence this trial after receiving interim data from the Ulcerative colitis (UC) trial (CALDOSE-1).